Advertisement

Travel Vaccination

  • Andrea Rossanese
Chapter
Part of the Practical Issues in Geriatrics book series (PIG)

Abstract

The World Tourism Organization estimated the number of international tourist arrivals to be 1.2 billion in 2016, an increase of 46 million over the previous year, a figure that has been rising constantly for 7 consecutive years. In this context, a long list of vaccines are dispensed and administered in travel clinics around the world. There are two main steps in immunizing travelers, namely, to update routine vaccinations and, second, to provide travel-specific immunization. For the first step, knowledge of a patient’s previous immunizations and personal medical history is necessary. For the second step, considerably more issues must be covered, including obtaining information about the patient’s projected itinerary, mode of travel, planned living conditions during the stay, and purpose of travel. This review focuses on three major and common travel vaccines, namely, yellow fever, dengue, and rabies. It should be remembered that vaccines exist both to protect the visited populations and the travelers, plus those the travelers come in contact with on their return from endemic areas. Travel should be used as a good opportunity to update routine vaccines.

Keywords

Travel Vaccine Dengue Rabies Yellow fever Travelers 

References

  1. 1.
    World Tourism Organization (UNWTO). UNWTO Annual Report 2016. UNWTO, Madrid, Spain. 2017. https://www.e-unwto.org/doi/pdf/10.18111/9789284418725. Accessed 29 June 2018.
  2. 2.
    Douam F, Ploss A. Yellow fever virus: knowledge gaps impeding the fight against an old foe. Trends Microbiol. 2018;26(11):913–28.CrossRefGoogle Scholar
  3. 3.
    World Health Organization. WHO global yellow fever data base. http://apps.who.int/globalatlas/default.asp. Accessed 30 June 2018. (Latest data for Yellow Fever from 2005).
  4. 4.
    World Health Organization. International Health Regulations. 3rd ed. 2005. http://www.who.int/ihr/publications/9789241580496/en/. Accessed 30 June 2018.
  5. 5.
    Meeting of the Strategic Advisory Group of Experts on immunization, April 2013—conclusions and recommendations. Wkly Epidemiol Rec. 2013;88(20):201–6.Google Scholar
  6. 6.
    Vaccines and vaccination against yellow fever. WHO position paper—June 2013. Wkly Epidemiol Rec. 2013;88(27):269–83.Google Scholar
  7. 7.
    Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP): summary report, February 26, 2015. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. http://www.cdc.gov/vaccines/acip/meetings/meetings-info.html. Accessed 30 June 2018.
  8. 8.
    Staples JE, Bocchini JA Jr, Rubin L, Fischer M, Centers for Disease C, Prevention. Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):647–50.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Tropical Med Int Health. 1999;4(12):867–71.CrossRefGoogle Scholar
  10. 10.
    Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26(48):6077–82.CrossRefGoogle Scholar
  11. 11.
    Ahuka-Mundeke S, Casey RM, Harris JB, Dixon MG, Nsele PM, Kizito GM, et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak—preliminary report. N Engl J Med. 2018.  https://doi.org/10.1056/NEJMoa1710430
  12. 12.
    Soentjens P, Andries P, Aerssens A, Tsoumanis A, Ravinetto R, Heuninckx W, et al. Pre-exposure intradermal rabies vaccination: a non-inferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days. Clin Infect Dis. 2018.  https://doi.org/10.1093/cid/ciy513
  13. 13.
    Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9(4):e0003709.CrossRefGoogle Scholar
  14. 14.
    Dodet B, Durrheim DN, Rees H. Rabies: underused vaccines, unnecessary deaths. Vaccine. 2014;32(18):2017–9.CrossRefGoogle Scholar
  15. 15.
    World Health Organization. Zero by 30: the global strategic plan to prevent human deaths from dog-transmitted rabies by 2030. 2017. http://www.who.int/rabies/Executive_summary_draft_V3_wlogo.pdf?ua=1. Accessed 1 July 2018.
  16. 16.
    Jonker EFF, Visser LG. Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study. J Travel Med. 2017;24(5).Google Scholar
  17. 17.
    World Health Organization. Rabies vaccines: WHO position paper—April 2018. Weekly Epidemiological Record No. 16, 2018, 93, 201–20. Weekly Epidemiological Record 2018;93(16):201–20. http://www.who.int/rabies/resources/who_wer9316/en/. Accessed 1 July 2018.
  18. 18.
    Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7.CrossRefGoogle Scholar
  19. 19.
    Anderson KB, Endy TP, Thomas SJ. The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy. Lancet Infect Dis. 2018;18(1):333–8.CrossRefGoogle Scholar
  20. 20.
    Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929–32.CrossRefGoogle Scholar
  21. 21.
    Dyer O. Philippines halts dengue immunisation campaign owing to safety risk. BMJ. 2017;359:j5759.CrossRefGoogle Scholar
  22. 22.
    Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327–40.CrossRefGoogle Scholar
  23. 23.
    Saez-Llorens X, Tricou V, Yu D, Rivera L, Jimeno J, Villarreal AC, et al. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis. 2018;18(2):162–70.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Andrea Rossanese
    • 1
  1. 1.Centre for Tropical Diseases, IRCCS “Sacro Cuore-Don Calabria”VeronaItaly

Personalised recommendations